Abstract:Due to its promising capacity in improving drug efficacy, polypharmacology has emerged to be a new theme in the drug discovery of complex disease. In the process of novel multi-target drugs (MTDs) discovery, in silico strategies come to be quite essential for the advantage of high throughput and low cost. However, current researchers mostly aim at typical closely related target pairs. Because of the intricate pathogenesis networks of complex diseases, many distantly related targets are found to play crucial role in synergistic treatment. Therefore, an innovational method to develop drugs which could simultaneously target distantly related target pairs is of utmost importance. At the same time, reducing the false discovery rate in the design of MTDs remains to be the daunting technological difficulty. In this research, effective small molecule clustering in the positive dataset, together with a putative negative dataset generation strategy, was adopted in the process of model constructions. Through comprehensive assessment on 10 target pairs with hierarchical similarity-levels, the proposed strategy turned out to reduce the false discovery rate successfully. Constructed model types with much smaller numbers of inhibitor molecules gained considerable yields and showed better false-hit controllability than before. To further evaluate the generalization ability, an in-depth assessment of high-throughput virtual screening on ChEMBL database was conducted. As a result, this novel strategy could hierarchically improve the enrichment factors for each target pair (especially for those distantly related/unrelated target pairs), corresponding to target pair similarity-levels.

Increasing the Odds of Drug Hit Identification by Screening Against Receptor Homologs?

Does Drug-Target Have A Likeness?

Learning the Drug Target-Likeness of A Protein

Compound Libraries: Recent Advances and Their Applications in Drug Discovery.

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Using Affinity Selection To Screen New Drugs In Combinatorial Libraries

Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.

A Novel Strategy for Designing the Magic Shotguns for Distantly Related Target Pairs

An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors

Diversity selection of compounds based on 'protein affinity fingerprints' improves sampling of bioactive chemical space

Measuring diversity: experimental design of combinatorial libraries for drug discovery.

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Recent advances in bioaffinity strategies for preclinical and clinical drug discovery: screening natural products, small molecules and antibodies

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening

Current Advances in Ligand‐based Target Prediction